T-2307
Based on 1 Customer Validation
T-2307, an arylamidine, has antifungal activities in vitro and in vivo. T-2307 exhibits broad-spectrum activity against clinically significant pathogens, including Candida species (MIC range, 0.00025 to 0.0078 μg/ml), Cryptococcus neoformans (MIC range, 0.0039 to 0.0625 μg/ml), and Aspergillus species (MIC range, 0.0156 to 4 μg/mL) .
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 873546-31-7
- Formule: C25H35N5O2
- Masse moléculaire:437.58
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Activité biologique
T-2307 exhibits potent activity against fluconazole-resistant and fluconazole-susceptible-dose-dependent Candida albicans strains as well as against azole-susceptible strains[1].
T-2307 shows efficacy in a murine model of candida glabrata infection despite in vitro trailing growth phenomena[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:C. glabrata ATCC 90030
-
Concentration:0.000125, 0.00025, 0.0005, 0.001, 0.002, 0.0039, 0.0078, 0.0156, 0.0313, 0.0625, 0.125 μg/mL
-
Incubation Time:24 and 48 hours
-
Result:C. glabrata exhibited significant trailing growth at concentrations between 0.0039 and 0.125 μg/mL at 48 h.
The trailing growth of C. glabrata at 24 h of incubation was similar to that at 48 h.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:4-week-old specific-pathogen-free ICR strain male mice bearing systemic infections with Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus[1].
-
Dosage:0.001, 0.1, 1 mg/kg
-
Administration:Subcutaneously administered; once a day for 7 days, beginning at 2 h after the infection.
-
Result:In the systemic infection caused by Candida albicans, all the control mice died by day 6. Mortality was significantly delayed in mice that were administered T-2307 at a dose of 0.01 mg/kg compared with that in the control mice. The calculated ED50s of T-2307were 0.00755 mg/kg.
In the systemic infection caused by Cryptococcus neoformans, all the control mice died by day 9. Mortality was significantly delayed in mice administered T-2307 at a dose of 0.1 mg/kg compared with that in the control mice. The calculated ED50s of T-2307 were 0.117 mg/kg.
In the systemic infection caused by Aspergillus fumigatus, all the control mice died by day 6. Mortality was significantly delayed in mice that were administered T-2307 at a dose of 1 mg/kg compared with that in the control mice. The calculated ED50s of T-2307 were 0.391 mg/kg.
Chemical Information
-
CAS No. 873546-31-7
-
Appearance Solid
-
Masse moléculaire 437.58
-
Formule C25H35N5O2
-
Color Off-white to light brown
-
SMILES
N=C(C1=CC=C(OCCCN2CCC(CCCOC3=CC=C(C(N)=N)C=C3)CC2)C=C1)N
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 50 mg/mL (114.26 mM; ultrasonic and adjust pH to 3 with HCl; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
1 M HCl : 12.5 mg/mL (28.57 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (270 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Junichi Mitsuyama, et al. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine. Antimicrob Agents Chemother. 2008 Apr;52(4):1318-24. [Content Brief]
[2]. Eio Yamada, et al. T-2307 shows efficacy in a murine model of Candida glabrata infection despite in vitro trailing growth phenomena. Antimicrob Agents Chemother. 2010 Sep;54(9):3630-4. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| 1 M HCl / DMSO | 1 mM | 2.2853 mL | 11.4265 mL | 22.8530 mL | 57.1324 mL |
| 5 mM | 0.4571 mL | 2.2853 mL | 4.5706 mL | 11.4265 mL | |
| 10 mM | 0.2285 mL | 1.1426 mL | 2.2853 mL | 5.7132 mL | |
| 15 mM | 0.1524 mL | 0.7618 mL | 1.5235 mL | 3.8088 mL | |
| 20 mM | 0.1143 mL | 0.5713 mL | 1.1426 mL | 2.8566 mL | |
| 25 mM | 0.0914 mL | 0.4571 mL | 0.9141 mL | 2.2853 mL | |
| DMSO | 30 mM | 0.0762 mL | 0.3809 mL | 0.7618 mL | 1.9044 mL |
| 40 mM | 0.0571 mL | 0.2857 mL | 0.5713 mL | 1.4283 mL | |
| 50 mM | 0.0457 mL | 0.2285 mL | 0.4571 mL | 1.1426 mL | |
| 60 mM | 0.0381 mL | 0.1904 mL | 0.3809 mL | 0.9522 mL | |
| 80 mM | 0.0286 mL | 0.1428 mL | 0.2857 mL | 0.7142 mL | |
| 100 mM | 0.0229 mL | 0.1143 mL | 0.2285 mL | 0.5713 mL |